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A new group of hybrid nitric oxide-releasing anti-inflammatory drugs (NONO-coxibs), in which an 
O2-acetoxymethyl-1-(N-ethyl-N-methylamino)diazen-1-ium-1,2-diolate NO-donor moiety is attached 
directly to the carboxylic acid group of 1-(4-aminosulfonylphenyl)-5-aryl-1H-pyrazol-3-carboxylic 
acids (6a–c), were synthesized. A low amount of NO was released from the diazen-1-ium-1,2-diolate 
compounds 6a–c upon incubation with phosphate buffer saline (PBS) at pH 7.4 (range: pH 7.97–8.51), 
whereas, the percentage of NO released was significantly higher (84.5%–85.05% of the theoretical 
maximal release of two molecules of NO/molecule of the parent hybrid ester prodrug) when the 
diazen-1-ium-1,2-diolate ester prodrugs were incubated in the presence of rat serum. These incubation 
studies demonstrated that both NO and the anti-inflammatory 1-(4-aminosulfonylphenyl)-5-(4-H, 4-F 
or 4-Me-phenyl)-1H-pyrazol-3-carboxylic acid (4a–c) would be released from the parent NONO-coxib 
upon in vivo cleavage by non-specific serum esterases. The parent compounds 4a-c displayed good anti-
inflammatory effects (ID50=81.4–112.4 mg/kg p.o.) between those exhibited by the reference drugs, aspirin 
(ID50=114.3 mg/kg p.o.) and celecoxib (ID50=12.6 mg/kg p.o.). Hybrid ester anti-inflammatory/NO-donor 
prodrugs (NONO-coxibs) offer a potential drug-design concept directed toward the development of anti-
inflammatory drugs that are lacking adverse ulcerogenic and/or cardiovascular effects.
Keywords: Anti-inflammatory/development/drugs. NONO-coxib esters. 1,5-dihydropyrazoles.
INTRODUCTION
Non-steroidal anti-inflammatory drugs (NSAIDs) 
represent a miscellaneous group of compounds that are 
essentially used to combat fever, pain, and inflammation. 
NSAIDs remain by far among the most commonly 
used classes of medications, accounting for 2.5% of all 
prescription dollars in the world (Trelle et al., 2011). 
NSAIDs exert their pharmacological action by inhibiting 
the synthesis of prostaglandins (PGs) by non-selectively 
blocking cyclooxygenases (COX)-1 and COX-2, or by 
selectively blocking COX-2. (Laine, 2002; Gunter et al., 
2017). COX-1 is constitutively expressed in many tissues, 
and it physiologically functions in the maintenance of 
renal function, the protection of gastric mucosa, and 
the regulation of platelet aggregation, while COX-2 is 
inducible by pro-inflammatory mediators (Gunter et al., 
2017). The use of NSAIDs that selectively inhibit the 
inducible COX-2 isozyme in the periphery provided a 
useful drug-design concept. This discovery resulted in the 
development of effective anti-inflammatory (AI) drugs 
that were devoid of adverse cardiovascular effects and 
gastrointestinal ulcerogenicity believed to be associated 
with inhibition of the constitutive cyclooxygenase 
isoform (COX-1) (Thomsen et al., 2006). Therefore, 
COX-2 selective inhibitors (coxibs), such as celecoxib, 
I, rofecoxib, II, and valdecoxib, III, (Figure 1) were 
developed for the long-term treatment of patients suffering 
from chronic pain and inflammation (Turini, DuBois, 
W. M. Soliman, K. R. A. Abdellatif, E. E. Knaus
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2002). Unfortunately, some selective COX-2 inhibitory 
drugs that include rofecoxib II and valdecoxib III alter 
the natural balance in the COX biochemical pathway. In 
this regard, the amount of desirable vasodilatory and anti-
aggregatory prostacyclin (PGI2) produced is decreased, 
and this is accompanied by a simultaneous increase in the 
level of the undesirable prothrombotic thromboxane A2 
(TxA2) (Hinz, Brune, 2002; Patel, Gross, 2002). These 
two adverse biochemical changes in the COX pathway are 
believed to be responsible for increased incidences of high 
blood pressure and myocardial infarction that ultimately 
prompted the withdrawal of rofecoxib, II and valdecoxib, 
III (Scheen, 2004; Dogné, Supuran, Pratico, 2005).
Nitric oxide (NO) displays a number of favorable 
pharmacological actions that include vascular relaxation 
(vasodilation) and inhibition of platelet aggregation 
and adhesion (Serafim et al., 2012). Brueggeman et 
al.(2009) found that celecoxib, but not rofecoxib, dilated 
preconstricted small mesenteric arteries. The authors 
attributed the vasodilatory activity of celecoxib to the 
enhancement of KCNQ potassium currents and the 
suppression of L-type voltage-sensitive calcium currents. 
NO was shown to exhibit some of the general properties of 
PGs within gastric mucosa, and thus it should augment the 
local mucosal defense mechanism, thereby compensating 
the reduced gastric PGs produced by NSAIDs (Vannini et 
al., 2015).
The last decade has seen an excessive development 
of NO-based hybrid drugs in which an appropriate NO-
releasing chemical moiety was linked to the parent – already 
marketed – drugs to refine the overall pharmacotherapeutic 
efficacy, as well as to reduce any related noxious effects 
(Serafim et al., 2012; Consalvi, Biava, Poce, 2015; 
Abdellatif et al., 2017). In vivo and in vitro studies 
on NO-aspirin displayed more potent antithrombic 
properties when compared to aspirin. Furthermore, in 
an animal model of chronic neurodegenerative disease, 
NO-flurbiprofen and NO-aspirin incapacitated the brain’s 
inflammatory response (Shinde, Modi, Kulkarni, 2017). In 
2011, Abdellatif and co-workers (Abdellatif et al., 2011) 
disclosed the anti-inflammatory and vascular-relaxing 
activity of a series of diazen-1-ium-1,2-diolated NO 
donor ester prodrugs of 3-(4-hydroxymethylphenyl)-
4-(4-methanesulfonylphenyl)-5H-furan-2-one. Other 
new perspectives of NO donor molecules, including 
cardioprotectives, have been discussed in a recent study in 
which the researchers revealed the molecular mechanism 
of NO action on blood vessels (Kruzliak, Kovacova, 
Pechanova, 2013; Martelli et al., 2013; Kruzliak, Novák, 
Novák, 2014). In 2014, Martinez et al. patented a series of 
NO-releasing guanidine coxibs capable of releasing NO 
through an enzymatic pathway involving the guanidine 
moiety while retaining the scaffold of celecoxib (Martinez 
et al., 2014). Furthermore, Kontrek et al. have revealed 
that the conjugation of celecoxib with an NO donor 
moiety retains the anti-inflammatory properties of the 
parent drug while improving cardiovascular safety and 
antitumor efficacy, which is in line with other drugs of 
the NO-NSAIDS class (Konturek et al., 2006). In another 
study by Knaus et al., the non-ulcerogenic NONO-NSAID 
ester prodrugs of aspirin (IV) and indomethacin (V) 
(Figure 1) that have an NO-donor diazen-1-ium-1,2-
diolate (NONOate) moiety that are effectively cleaved 
by esterases to release the AI drug and NO, were reported 
(Velázquez et al., 2008). Therefore, the attachment of a 
NO-donor moiety to highly selective COX-2 inhibitors 
(NONO-coxibs) offers a potential drug-design concept that 
can be leveraged to outwit adverse cardiovascular events 
(Martelli et al., 2013).
Diazen-1-ium-1,2-diolate ions, after their cleavage 
from the parent hybrid NONO-coxib, can release up to two 
equivalents of NO without further metabolic activation. 
These ions are structurally diverse and they possess a rich 
derivatization chemistry that facilitates delivery of NO to 
specific organ and/or tissue sites (Keefer, 2003). These 
features distinguish the NONO-coxib IV and V (Figure 1) 
from nitrate-based NO-coxibs (NMI-1093, Figure 1), 
which require redox activation before NO is released 
(Dhawan et al., 2005).
Accordingly, the attachment of a N-diazen-1-ium-
1,2-diolate moiety offers a potential drug-design concept 
to circumvent the adverse cardiovascular events associated 
with the chronic clinical use of highly selective COX-2 
inhibitors.
RESULTS AND DISCUSSION
A COX-2 pharmacophore, such as methanesulfonyl, 
sulfonamide, methanesulfonamide, azido, or tetrazole, 
is required at the R1 position on the N1-phenyl ring for 
potent and selective COX-2 inhibitory activity (Zarghi 
et al., 2011; Zarghi et al., 2012). Studying the CYP2C9 
structure–metabolism relationships to optimize the 
metabolic stability of COX-2 inhibitors, Ahlstrom et 
al. revealed that the pyrazole ring C-3 position (R2 
substituent) imposes very few steric restrictions pertaining 
to COX-2 inhibitors, implying that the inhibitory 
properties of the COX-2 isozyme should be retained 
(Ahlström et al., 2007). It was also disclosed that the 
R2 carboxyl substituent at the C-3 position containing 
compounds may undergo an electrostatic interaction with 
Arg120 in the binding pocket of the COX-2 enzyme. The 
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R3 methyl substituent (benzylic carbon) in celecoxib (see 
the structure in Figure 2) undergoes sequential metabolic 
biotransformation to inactive metabolites; 
Me → CH2OH → CO2H → CO2  glucuronide conjugate) 
thus, it was concluded that the R3 carboxyl substituent on 
the pyrazole C-5 phenyl ring was not tolerable (Abdellatif 
et al., 2009). Based on this structural information, it 
was decided that the O2-acetoxymethyl-1-(N-ethyl-N-
methylamino) diazen-1-ium-1,2-diolate NO-donor moiety 
be coupled to a pyrazole ring from the C-3 CO2H group via 
an ester moiety to prepare the target NONO–coxib hybrid 
ester prodrugs (6a–c).
The percentage of NO released from the hybrid 
ester prodrugs (6a–c) upon incubation in phosphate 
buffered saline (PBS; pH 7.4), and in the presence of rat 
serum, was calculated (see data in Table I). One type of 
chemical modification was used to control the rate of 
NO release from diazen-1-ium-1,2-diolate; this is the 
attachment of alkyl substituents to the O2-position (Huang 
et al., 2012). O2-substituted-diazen-1-ium-1,2-diolates 
are stable compounds that hydrolyze slowly, even in an 
acidic solution (Hrabie et al., 1993). Consistent with these 
observations, when compounds 6a–c were incubated for 
1.5 hours in PBS at pH 7.4, the percentage of NO released 
varied from 7.97% to 8.51%, suggesting slow NO release. 
Conversely, the effect of non-specific esterases present in 
rat serum was higher (range: 65.9%–74.0%). These data 
indicate that the non-specific serum esterases present 
in rat serum cleave these hybrid prodrug esters more 
effectively than PBS at pH 7.4. The hybrid ester prodrugs 
6a–c cannot release NO prior to cleavage of the acetoxy 
moiety present in the terminal O2-acetoxymethyl-1-(N-
methylamino)diazen-1-ium-1,2-diolate NO-donor moiety. 
This requirement is consistent with the observation that 
the O2-sodium diazen-1-ium-1,2-diolate, which does not 
possess an ester group that requires prior ester cleavage, 
releases 84.5% and 85.0% of the theoretical maximal 
release of two molecules of NO and the molecule of 
the parent NO donor, respectively, as disclosed earlier 
(Abdellatif et al., 2008). An earlier study revealed that 
there are two possible pathways for the ester hydrolysis of 
hybrid ester prodrugs containing an O2-acetoxymethyl-1-
[N-(2-ethoxy)-N-methylamino] diazen-1-ium-1,2-diolate 
moiety. Moreover, the study described the subsequent 
release of acetic acid, formaldehyde, two molecules 
of NO, and N-methylethanolamine (Velázquez et al., 
2007). The hybrid ester NO-donor prodrugs 6a–c were 
designed with a one-carbon methylene spacer between the 
terminal acetoxy group and the diazen-1-ium-1,2-diolate 
O2-atom, such that the O2-(hydroxymethyl)diazen-1-
FIGURE 1 - Chemical structure of the selective COX-2 inhibitors celecoxib (I), rofecoxib (II), and valdecoxib (III), diazen-1-ium-
diolate ester prodrugs of Aspirin (IV) and indomethacin (V), and nitrate-based prodrug (NMI-1093).
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ium-1,2-diolate compound formed following cleavage of 
the acetoxy group; this would spontaneously eliminate 
formaldehyde to produce the free diazen-1-ium-1,2-diolate 
compound that can subsequently fragment to release two 
molecules of NO. Contrariwise, cleavage of the second 
ester group attached directly to the C-3 position of the 
pyrazole ring, which releases the parent coxib 4a–c, can 
occur either prior to or after NO release has occurred. 
The NO release properties of compounds 6a–c were 
significant. Compounds 4a–c exhibited AI activities 
(ID50 = 85.2-104.4 mg/kg p.o. range) between those 
exhibited by the reference drugs, aspirin (ID50 = 128.7 mg/kg 
p.o.) and celecoxib (ID50 = 10.8 mg/kg p.o.). The 
relative potency profile relative to the R-substituent was 
Me > F ≈ H. These AI data are aligned with the COX 
inhibition assay data, in which the prodrug with the 
R = Me displayed the highest COX-2 selectivity (SI) 
toward COX-enzyme, as compound 6c shares the same 
R3 methyl substituent as celecoxib (c.f. Figure 2). In an 
earlier study by Kanus and co-workers, (Abdellatif et 
al., 2008), the anti-inflammatory activity of a new series 
of diazen-1-ium-1,2-diolated NO donor ester prodrugs 
of 1-(4-methanesulfonylphenyl)-5-aryl-1H-pyrazol-
3-carboxylic acids showed a similar potency profile 
with regard to the aryl substitution at the 5-position of 
the pyrazole ring. The AI activities exhibited by the 
hybrid ester prodrugs 6a–c were not determined in 
this study, as it was previously reported that the same 
hybrid ester prodrug analogs of aspirin, ibuprofen, and 
indomethacin exhibited similar AI activities to aspirin, 
ibuprofen, and indomethacin for comparable ID50 µmol/kg 
oral dosage regimens (Velázquez et al., 2007).
Methodology
Chemistry
A group of 1-(4-aminosulfonylphenyl)-5-aryl-
1H-pyrazol-3-carboxylate esters possessing an O2-
acetoxymethyl-1-(N-ethyl-N-methylamino)diazen-1-
ium-1,2-diolate ester moiety (6a–c) were synthesized 
using the reaction sequence illustrated in Scheme 1. 
Accordingly, the reaction of 2,4-diketo ester 1a–c with 
(4-aminosulfonylphenyl)hydrazine hydrochloride (2) 
under reflux in ethanol will provide the corresponding 
pyrazole esters (3a–c). Alkaline hydrolysis of the esters 
(3a–c) with LiOH yielded the respective acids (4a–c). 
Nucleophilic displacement of the mesyloxy group present 
in the mesylate (5) by the respective sodium salt of 
the obtained acids 4a–c in hexamethylphosphoramide 
(HMPA) furnished the target O2-acetoxymethyl-1-
(N-ethyl-N-methylamino) diazen-1-ium-1,2-diolate 
1-(4-amino-sulfonylphenyl)-5-aryl-1H-pyrazol-3-
carboxylate (6a–c).
The starting materials, methyl 2-hydroxy-4-oxo-
4-aryl-2-butenoate (1a–c) (Abdellatif et al., 2008), 
were prepared as follows: A solution of diethyloxalate 
and either acetophenone 1a, 4-fluoroacetophenone 1b, 
or 4-methylacetophenone 1c in methanol was added 
dropwise to a solution of NaOH in MeOH, and the 
reaction was then refluxed for 2 hours. After cooling to 
room temperature, the mixture was poured into water 
acidified with HCl and extracted with diethylether. The 
combined extract was washed, dried over MgSO4, and 
then the solvent was removed in a vacuum. Conversely, 
(4-aminosulfonylphenyl)hydrazine hydrochloride 
(2) (Soliman, 1979) and O2-acetoxymethyl-1-[N-(2-
methylsulfonyloxyethyl)-N-methylamino] diazen-1-ium-
1,2-diolate (5) (Velázquez, Knaus, 2004) were prepared 
according to a literature procedure.
Characterization of the synthesized novel compounds 
was done using a specific melting point, Fourier-transform 
infrared (FT-IR), and 1H nuclear magnetic resonance 
(NMR), which were available at the College of Clinical 
Pharmacy, King Faisal University.
Statistical analysis
The results will be expressed as the mean ± standard 
error of the mean. The treated groups were compared 
with the controls to assess any statistically significant 
differences (P<0.05) using paired Student’s t-test 
(IBM SPSS Statistics for Windows, Version 22.0; IBM 
Corporation, Armonk, NY, USA).
Cyclooxygenase inhibition assay
The ability of the test compounds to inhibit bovine 
COX-1 and human recombinant COX-2 was determined 
using an enzyme-immunoassay (EIA) kit following a 
previously reported procedure using a 96-well plate (Rao 
FIGURE 2 - Generic 1,5-diaryl-3-substituted-pyrazole selective 
COX-2 structure based on the structure of celecoxib (R1 = 
SO2NH2, R2 = CF3, R3 = CH3).
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et al., 2003). The procedure is described as follows: (a) 
200 μL of Ellman’s reagent was added to all 96 wells; (b) 
the plate was covered with a thin film; (c) the plate was 
incubated at room temperature for 90 minutes in the dark 
to develop the color; and (d) an ultraviolet (UV) plate 
reader was used at wavelengths ranging from 405–420 nm.
Nitric oxide release assay
The test compound was incubated at 37 °C for 
1.5 hours with either 2.4 mL of a 1.0×10–2 mM solution 
in phosphate buffer at pH 7.4, or with 2.4 mL of a 
1.0×10–2 mM solution in phosphate buffer at pH 7.4 to 
which 90 l L rat serum was added. It was then possible to 
determine the in vitro NO release via quantification of the 
nitrite produced by the reaction of NO with oxygen and 
water using the Griess reaction. NO release data were 
acquired for the test compounds (6a–c) using the reported 
procedures (Chowdhury et al., 2010).
In vivo anti-inflammatory assay
The anti-inflammatory profiles of the test compounds 
and reference drugs, celecoxib and aspirin, were evaluated 
using an in vivo carrageenan-induced foot paw edema 
model, as reported previously (Winter, Risley, Nuss, 
1962).
CONCLUSIONS
A new group of hybrid ester prodrugs (NONO-
coxibs) in which an O2-acetoxymethyl-1-(N-ethyl-N-
methylamino)diazen-1-ium-1,2-diolate (6a–c) NO-donor 
moiety is attached directly to the carboxylic acid group 
of 1-(4-aminosulfonylphenyl)-5-(4-H, 4-F or 4-Me-
phenyl)-1H-pyrazol-3-carboxylic acids (4a–c) were 
synthesized for a comparative biological evaluation. 
Compound 6c, where R= Me, displayed the highest AI 
activity and COX-2 selectivity, but it was still lower 
than that exhibited by celecoxib. In terms of biological 
stability, the NO-release studies (a) showed that the 
NONO-coxib prodrugs (6a–c) are relatively stable in PBS 
at pH 7, where the NO release is in the 7.97–8.51 range; 
(b) highlighted that the O2-acetoxymethyl-1-(N-ethyl-N-
SCHEME 1 - Reagents and conditions: (a) EtOH, reflux, 3 h; (b) THF/MeOH, LiOH (2 M), RT, 15 h; (c) Na2CO3, 
hexamethylphosphoramide (HMPA), 25 °C, 96 h.
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methylamino)diazen-1-ium-1,2-diolates (6a–c) undergo 
extensive cleavage of the terminal acetoxy group by rat 
serum esterase(s), which is followed by a significant NO 
release in the 60.51%–71.71% range; and (c) suggested 
that an alternative linker group to the ester moiety attached 
directly to the C-3 position of the pyrazole ring is vital to 
provide more potent AI activity.
EXPERIMENTAL SECTION
General. Melting points were determined on a 
Thomas–Hoover capillary apparatus and are uncorrected. 
Infrared (IR) spectra were recorded as films on NaCl plates 
using a Nicolet 550 Series II Magna FT-IR spectrometer. 
1H NMR spectra were measured on a Bruker AM-300 
spectrometer in D2O, CDCl3, or DMSO-d6 with TMS as the 
internal standard, where J (coupling constant) values are 
estimated in Hertz (Hz). Microanalyses were performed for 
C, H, N (Micro Analytical Service Laboratory, Department 
of Chemistry, University of Alberta, Edmonton, Alberta, 
Canada) and were within ±0.4% of the theoretical values. 
Silica gel column chromatography was performed using 
a Merck silica gel 60 ASTM (70–230 mesh). All other 
reagents, purchased from the Aldrich Chemical Company 
(Milwaukee, WI, USA), were used without further 
purification. Methyl 2-hydroxy-4-oxo-4-aryl-2-butenoate 
(1a–c) (Abdellatif et al., 2010), (4-aminosulfonylphenyl)
hydrazine hydrochloride (2), (Pommery et al., 2004), and 
O2-acetoxymethyl-1-[N-(2-methylsulfonyloxyethyl)-N-
methylamino]diazen-1-ium-1,2-diolate (5) (Velázquez 
& Knaus, 2004) were prepared according to a literature 
procedure. 
G e n e r a l  m e t h o d  f o r  p re p a r i n g  m e t h y l 
1-(4-aminosulfonylphenyl)-5aryl-1H-pyrazole-3-
carboxylates (3a–c). (4-Aminosulfonylphenyl)hydrazine 
hydrochloride (2) (0.982 g, 4.4 mmol) was added to a 
stirred solution of the dione 1a, 1b, or 1c (4.0 mmol) in 
50 mL of EtOH. The mixture was heated to reflux and 
stirred for 3 hours. After cooling to room temperature, the 
reaction mixture was concentrated in vacuo. The residue 
was taken up in EtOAc, washed with water and brine, dried 
over MgSO4, filtered, and concentrated in vacuo to give 
3a–c. Physical and spectral data are listed below.
Methyl 1-(4-aminosulfonylphenyl)-5-phenyl-
1H-pyrazole-3-carboxylate (3a). 78% yield; pale 
brown powder; IR (film) 3349, 3261 (NH2), 2960 (C-H 
aromatic), 2913 (C-H aliphatic), 1723 (CO2), 1341, 1161 
(SO2) cm
-1; 1H NMR (CDCl3 + DMSO-d6) δ 3.72 (s, 3H, 
OCH3), 6.79(s, 1H, pyrazole H-4), 6.94 (s, 2H, NH2, D2O 
exchangeable), 7.00-7.06 (m, 3H, phenyl H-3, H-4, H-5), 
TABLE I - In vivo anti-inflammatory activities for 1-(4-methanesulfonylphenyl)-5-(4-substitutedphenyl)-1H-pyrazol-3-carboxylic 
acid (4a-c), and percent (%) nitric oxide release, data for diazeniumdiolate pyrazole esters (6a-c) and in vitro COX-1 and COX-2 
inhibition.
Compound R AI activity
a 
ID50 (mg/kg)
% •NO releasedb IC50e (µM) COX-2 S.I.f
PBSc Serumd COX-1 COX-2
4a H 112.4±7.6 — —
4b F 110.1±6.8 — —
4c Me 81.2±5.9 — —
6a H — 7.97±0.62 71.71±6.3 11.3±1.1 3.2±0.27 3.53
6b F — 9.04±0.81 65.91±5.8 3.1±0.25 0.7±0.06 4.42
6c Me — 8.51±0.72 73.91±6.7 5.6±0.49 1.1±0.98 5.1
Celecoxib 12.6±1.1 7.7±0.63 0.12±0.01 64.2
Aspirin 114.3±10.9 0.3±0.02 2.4±0.19 0.13
aInhibitory activity in a carrageenan-induced rat paw edema assay. The results are expressed as the ID50 value (mg/kg) at 3 h after 
oral administration of the test compound. bPercent of nitric oxide released based on a theoretical maximum release of 2 mol of NO/
mol of the dia zen-1-ium-1,2-diolate test compounds (6a-c). The result is the mean value of 3 measurements (n = 3) where variation 
from the mean % value was ≤ 0.5%. cA solution of the test compound (2.4 mL of a 1.0 x 10-2 mM solution in phosphate buffer at 
pH 7.4), was incubated at 37 °C for 1.5 h. dA solution of the test compound (2.4 mL of a 1.0 x 10-2 mM solution in phosphate buffer 
at pH 7.4 to which 90 µL rat serum had been added), was incubated at 37 °C for 1.5 h. eThe in vitro test compound concentration 
required to produce 50% inhibition of ovine COX-1 or human recombinant COX-2. The result (IC50, µM) is the mean of two 
determinations acquired using the enzyme immune-assay kit (Catalog No. 560131, Cayman Chemicals Inc., Ann Arbor, MI, USA) 
and the deviation from the mean is <10% of the mean value. fIn vitro COX-2 selectivity index (COX-1- IC50/COX-2 IC50)
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7.12-7.17 (m, 2H, phenyl H-2, H-6), 7.21 (d, J = 7.2 Hz, 
2H, aminosulfonylphenyl H-2, H-6), 7.68 (d, J = 7.2 Hz, 
2H, aminosulfonylphenyl H-3, H-5). 
Methy l  1 - (4 -aminosu l fony lpheny l ) -5 - (4-
fluorophenyl)-1H-pyrazole-3-carboxylate (3b). 75% 
yield; pale brown powder; IR (film) 3341, 3222 (NH2), 
2958 (C-H aromatic), 2922 (C-H aliphatic), 1733 (CO2), 
1339, 1160 (SO2) cm
-1; 1H NMR (CDCl3 + DMSO-d6) δ 
3.84 (s, 3H, OCH3), 6.90 (s, 1H, pyrazole H-4), 6.93 (s, 2H, 
NH2, D2O exchangeable), 6.95-6.99 (m, 2H, fluorophenyl 
H-2, H-6), 7.13 (m, 2H, fluorophenyl H-3, H-5), 7.31 (dd, 
J = 8.7, 2.2 Hz, 2H, aminosulfonylphenyl H-2, H-6), 7.81 
(dd, J = 8.7, 2.2 Hz, 2H, aminosulfonylphenyl H-3, H-5), 
Methy l  1 - (4 -aminosu l fony lpheny l ) -5 - (4-
methylphenyl)-1H-pyrazole-3-carboxylate (3c). 89% 
yield; white powder; IR (film) 3348, 3256 (NH2), 2957 
(C-H aromatic), 2918 (C-H aliphatic), 1724 (CO2), 1337, 
1165 (SO2) cm
-1; 1H NMR (CDCl3 + DMSO-d6) δ 2.28 
(s, 3H, CH3), 3.86 (s, 3H, OCH3), 6.89 (s, 1H, pyrazole 
H-4), 6.90 (s, 2H, NH2, D2O exchangeable), 7.02 (d, 
J = 8.1, 2H, methylphenyl H-3, H-5), 7.08 (d, J = 8.1, 
2H, methylphenyl H-2, H-6), 7.35 (d, J = 8.5 Hz, 2H, 
aminosulfonylphenyl H-2, H-6), 7.82 (d, J = 8.5 Hz, 2H, 
aminosulfonylphenyl H-3, H-5). 
G e n e r a l  m e t h o d  f o r  p r e p a r i n g 
1-(4-aminosulfonylphenyl)-5-aryl-1H-pyrazol-3-
carboxylic acids (4a–c). The appropriate ester 3a, 3b, or 
3c (1.40 mmol), was added to a stirred solution of THF (50 
mL), MeOH (50 mL), and LiOH (2 M, 50 mL) and stirred 
for 15 hours. NaOH (1 M, 200 mL) was added and the 
mixture was extracted with EtOAc (200 mL). The aqueous 
phase was acidified with concentrated HCl (38 mL) to a 
pH level of 1.0, extracted with EtOAc (300 mL), dried 
over MgSO4, and filtered and concentrated under vacuum 
to give the respective acids 4a–c, for which physical and 
spectral data are listed below.
1-(4-Aminosulfonylphenyl)-5-phenyl-1H-pyrazol-
3-carboxylic acid (4a). 83% yield; pale brown powder; 
mp 181-182 °C ; IR (film) 3628-3271 (OH, NH2), 3070 
(C-H aromatic), 3005 (C-H aliphatic), 1711 (CO2), 1312, 
1151 (SO2) cm
-1; 1H NMR (CDCl3 + DMSO-d6) δ 6.68 
(s, 2H, NH2, D2O exchangeable), 6.75 (s, 1H, pyrazole 
H-4), 6.96-6.99 (m, 3H, phenyl H-3, H-4, H-5), 7.08-
7.12 (m, 2H, phenyl H-2, H-6), 7.20 (d, J = 8.5 Hz, 2H, 
aminosulfonylphenyl H-2, H-6), 7.64 (d, J = 8.5 Hz, 2H, 
aminosulfonylphenyl H-3, H-5), 11.99 (br. s, 1H, COOH, 
D2O exchangeable); MS 366.05 (M + Na). 
1-(4-Aminosulfonylphenyl)-5-(4-fluorophenyl)-
1H-pyrazol-3-carboxylic acid (4b). 65% yield; pale 
brown powder; mp 213-215 °C ; IR (film) 3637-3267 
(OH, NH2), 3069 (C-H aromatic), 3011 (C-H aliphatic), 
1710 (CO2), 1322, 1168 (SO2) cm
-1; 1H NMR (CDCl3 + 
DMSO-d6) δ 6.90 (s, 1H, pyrazole H-4), 6.96 (s, 2H, NH2, 
D2O exchangeable), 7.01-7.05 (m, 2H, fluorophenyl H-2, 
H-6), 7.13-7.18 (m, 2H, fluorophenyl H-3, H-5), 7.34 (d, 
J = 8.5 Hz, 2H, aminosulfonylphenyl H-2, H-6), 7.81 (d, 
J = 8.5 Hz, 2H, aminosulfonylphenyl H-3, H-5), 12.53 (br. 
s, 1H, COOH, D2O exchangeable); MS 384.04 (M + Na). 
1-(4-Aminosulfonylphenyl)-5-(4-methylphenyl)-1H-
pyrazol-3-carboxylic acid (4c). 71% yield; white powder; 
mp 242-243 °C ; IR (film) 3574-3273 (OH, NH2), 3071 
(C-H aromatic), 3008 (C-H aliphatic), 1716 (CO2), 1319, 
1156 (SO2) cm
-1; 1H NMR (CDCl3 + DMSO-d6) δ 2.31 
(s, 3H, CH3), 6.79 (s, 2H, NH2, D2O exchangeable), 6.91 
(s, 1H, pyrazole H-4), 7.05 (d, J = 8.1, 2H, methylphenyl 
H-3, H-5), 7.11 (d, J = 8.1, 2H, methylphenyl H-2, H-6), 
7.40 (d, J = 8.5 Hz, 2H, aminosulfonylphenyl H-2, H-6), 
7.84 (d, J = 8.5 Hz, 2H, aminosulfonylphenyl H-3, H-5); 
MS 380.08 (M + Na).
General  method for  prepar ing  o f  the  O 2-
acetoxymethyl-1-(N-ethyl-N-methylamino) diazen-1-ium-
1,2-diolate pyrazole esters (6a-c). Sodium carboxylates of 
the respective acids 5a-c (R = H, , F, Me) were prepared 
in situ by stirring each acid (2.5 mmol) in a suspension 
of sodium carbonate (0.27 g, 2.5 mmol) and HMPA (3.5 
mL) for 24 h at 25 °C. A solution of O2-acetoxymethyl-1-
[N-(2-methylsulfonyloxyethyl)-N-methylamino]diazen-
1-ium-1,2-diolate (5, 2.5 mmol) in HMPA (1.5 mL) was 
then added, and the reaction was allowed to proceed for 
72 h at 25 °C. EtOAc (30 mL) was added, the mixture was 
washed with water (5 × 15 mL), the organic phase was 
dried (Na2SO4), and the solvent was removed in vacuo. 
The residue obtained was purified by silica gel column 
chromatography using EtOAc /hexane (2:1, v/v) as eluent 
to afford the respective product 6a, 6b or 6c for which the 
physical and spectral data are listed below.
O2-Acetoxymethyl-1-(N-ethyl-N-methylamino)
diazen-1-ium-1,2-diolate 1-(4-aminosulfonylphenyl)-5-
phenyl-1H-pyrazol-3-carboxylate (6a). Yield, 26%; white 
powder; mp 63-65 °C; IR (film) 3341, 3257 (NH2), 2982 
(C-H aromatic), 2934 (C-H aliphatic), 1738 (CO2), 1339, 
1165 (SO2), 1226, 1065 (N=N-O) cm
-1; 1H NMR (CDCl3) 
δ 2.08 (s, 3H, COCH3), 3.19 (s, 3H, NCH3), 3.85, (t, J = 5.5 
Hz, 2H, CH2N), 4.59 (t, J = 5.5 Hz, 2H, CO2CH2), 5.09 (s, 
2H, NH2, D2O exchangeable), 5.73 (s, 2H, OCH2O), 7.03 
W. M. Soliman, K. R. A. Abdellatif, E. E. Knaus
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(s, 1H, pyrazole H-4), 7.20-7.26 (m, 3H, phenyl H-3, H-4, 
H-5), 7.37-7.41 (m, 2H, phenyl H-2, H-6), 7.47 (d, J = 6.8 
Hz, 2H, aminosulfonylphenyl H-2, H-6), 7.55 (d, J = 6.8 
Hz, 2H, aminosulfonylphenyl H-3, H-5), MS 555.12 (M 
+ Na); Anal. Calcd for C22H24N6O8S: C, 49.62; H, 4.54; N, 
15.72. Found: C, 49.55; H, 4.62; N, 15.89. 
O2-Acetoxymethyl-1-(N-ethyl-N-methylamino)
diazen-1-ium-1,2-diolate 1-(4-aminosulfonylphenyl)-5-(4-
fluorophenyl)-1H-pyrazol-3-carboxylate (6b). Yield, 21%; 
white powder; mp 66-68 °C; IR (film) 3360, 3251 (NH2), 
2972 (C-H aromatic), 2935 (C-H aliphatic), 1729 (CO2), 
1344, 1167 (SO2), 1221, 1062 (N=N-O) cm
-1; 1H NMR 
(CDCl3) δ 2.08 (s, 3H, COCH3), 3.18 (s, 3H, NCH3), 3.84 
(t, J = 5.5 Hz, 2H, CH2N), 4.59 (t, J = 5.5 Hz, 2H, CO2CH2), 
5.05 (s, 2H, NH2, D2O exchangeable), 5.74 (s, 2H, OCH2O), 
7.02 (s, 1H, pyrazole H-4), 7.08-7.11 (m, 2H, fluorophenyl 
H-2, H-6), 7.20-7.24 (m, 2H, fluorophenyl H-3, H-5), 7.46 
(d, J = 6.8 Hz, 2H, aminosulfonylphenyl H-2, H-6), 7.91 (d, 
J = 6.8 Hz, 2H, aminosulfonylphenyl H-3, H-5); MS 572.97 
(M + Na). Anal. Calcd for C22H23FN6O8S: C, 48; H, 4.21; 
N, 15.27. Found: C, 48.22; H, 4.32; N, 15.38. 
O2-Acetoxymethyl-1-(N-ethyl-N-methylamino)
diazen-1-ium-1,2-diolate 1-(4-aminosulfonylphenyl)-5-
(4-methylphenyl)-1H-pyrazol-3-carboxylate (6c). Yield, 
35%; white crystals; mp 142-144 °C; IR (film) 3347, 
3257 (NH2), 2965 (C-H aromatic), 2920 (C-H aliphatic), 
1733 (CO2), 1345, 1165 (SO2), 1226, 1068 (N=N-O) cm
-
1; 1H NMR (CDCl3) δ 2.09 (s, 3H, COCH3), 2.38 (s, 3H, 
CH3), 3.19 (s, 3H, NCH3), 3.85, (t, J = 5.5 Hz, 2H, CH2N), 
4.59 (t, J = 5.5 Hz, 2H, CO2CH2), 5.18 (s, 2H, NH2, D2O 
exchangeable), 5.74 (s, 2H, OCH2O), 7.00 (s, 1H, pyrazole 
H-4), 7.10 (d, J = 7.9 Hz, 2H, methylphenyl H-2, H-6), 
7.17 (d, J = 7.9 Hz, 2H, methylphenyl H-3, H-5), 7.47 (d, 
J = 6.7 Hz, 2H, aminosulfonylphenyl H-2, H-6), 7.88 (d, J 
= 6.7 Hz, 2H, aminosulfonylphenyl H-3, H-5),; MS 569.14 
(M + Na). Anal. Calcd for C23H26N6O8S.1/2H2O: C, 50.54; 
H, 4.79; N, 15.38. Found: C, 50.78; H, 4.90; N, 15.52. 
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